ACP
Acuta Capital Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-660,000
| Closed | -$2.27M | – | 51 |
|
|
2020
Q3 | $2.27M | Sell |
660,000
-1,240,000
| -65% | -$4.26M | 0.62% | 37 |
|
|
2020
Q2 | $9.05M | Buy |
1,900,000
+1,650,000
| +660% | +$7.86M | 2.62% | 12 |
|
|
2020
Q1 | $500K | Sell |
250,000
-2,575,000
| -91% | -$5.15M | 0.24% | 30 |
|
|
2019
Q4 | $9.75M | Buy |
+2,825,000
| New | +$9.75M | 2.41% | 12 |
|
|
2019
Q2 | – | Sell |
-25,000
| Closed | -$204K | – | 31 |
|
|
2019
Q1 | $204K | Hold |
25,000
| – | – | 0.1% | 31 |
|
|
2018
Q4 | $202K | Buy |
+25,000
| New | +$202K | 0.15% | 17 |
|
|
2018
Q1 | – | Sell |
-900,000
| Closed | -$4.42M | – | 37 |
|
|
2017
Q4 | $4.42M | Sell |
900,000
-96,300
| -10% | -$473K | 0.83% | 17 |
|
|
2017
Q3 | $5.22M | Buy |
996,300
+827,615
| +491% | +$4.34M | 0.94% | 16 |
|
|
2017
Q2 | $938K | Sell |
168,685
-751,625
| -82% | -$4.18M | 0.26% | 31 |
|
|
2017
Q1 | $7.73M | Buy |
920,310
+770,310
| +514% | +$6.47M | 1.83% | 10 |
|
|
2016
Q4 | $950K | Sell |
150,000
-404,448
| -73% | -$2.56M | 0.35% | 31 |
|
|
2016
Q3 | $2.45M | Buy |
+554,448
| New | +$2.45M | 0.92% | 28 |
|
|
2015
Q4 | – | Sell |
-271,399
| Closed | -$3.09M | – | 53 |
|
|
2015
Q3 | $3.09M | Buy |
+271,399
| New | +$3.09M | 1.79% | 17 |
|